Regeneron Pharmaceuticals (REGN) Interest Expenses (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Interest Expenses of $52.5 million for Q2 2026, up 414.71% year-over-year from $10.2 million in Q2 2025, and up 85.51% quarter-over-quarter from $28.3 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Interest Expenses (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Interest Expenses history runs 18 years deep, the most recent figure standing at $52.5 million for Q2 2026.
- In Q2 2026, Interest Expenses rose 414.71% year-over-year to $52.5 million; the TTM figure through Jun 2026 stood at $52.5 million (up 414.71% YoY), while the FY2025 annual figure was $124.0 million, down 80.48% from the prior year.
- Interest Expenses for Q2 2026 stood at $52.5 million, up from $28.3 million in the prior quarter.
- The five-year high for Interest Expenses was $346.8 million in Q3 2022, with the low at $7.9 million in Q4 2024.
- The 5-year median for Interest Expenses is $40.4 million (2026), against an average of $109.1 million.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses surged 2342.25% in 2022, then sank 88.88% in 2025.
- Regeneron Pharmaceuticals' Interest Expenses stood at $17.4 million in 2022, then gained by 5.75% to $18.4 million in 2023, then slumped by 57.07% to $7.9 million in 2024, then climbed by 26.58% to $10.0 million in 2025, then surged by 425.0% to $52.5 million in 2026.
- Business Quant data shows REGN's Interest Expenses at $52.5 million in Q2 2026, $28.3 million in Q1 2026, and $10.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 6.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.50 Mn |
| Jun 30, 2026 | 52.50 Mn |
| Mar 31, 2026 | 28.30 Mn |
| Mar 31, 2026 | 28.30 Mn |
| Dec 31, 2025 | 64.10 Mn |
| Dec 31, 2025 | 64.10 Mn |
| Sep 30, 2025 | 19.30 Mn |
| Sep 30, 2025 | 19.30 Mn |
| Jun 30, 2025 | 10.20 Mn |
| Jun 30, 2025 | 10.20 Mn |
| Mar 31, 2025 | 17.70 Mn |
| Mar 31, 2025 | 17.70 Mn |
| Dec 31, 2024 | 45.50 Mn |
| Dec 31, 2024 | 45.50 Mn |
| Sep 30, 2024 | 26.00 Mn |
| Sep 30, 2024 | 26.00 Mn |
| Jun 30, 2024 | 91.70 Mn |
| Jun 30, 2024 | 91.70 Mn |
| Mar 31, 2024 | 104.70 Mn |
| Mar 31, 2024 | 104.70 Mn |